Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
TGTX

TGTX - TG Therapeutics Inc Stock Price, Fair Value and News

$49.53+1.48 (+3.08%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

76/100

TGTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

76/100

TGTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TGTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TGTX Price Action

Last 7 days

23.3%

Last 30 days

16.1%

Last 90 days

77.1%

Trailing 12 Months

32.5%

TGTX RSI Chart

TGTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TGTX Valuation

Market Cap

7.6B

Price/Earnings (Trailing)

16.42

Price/Sales (Trailing)

10.83

EV/EBITDA

49.97

Price/Free Cashflow

-534.33

TGTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TGTX Fundamentals

TGTX Revenue

Revenue (TTM)

700.3M

Rev. Growth (Yr)

69.56%

Rev. Growth (Qtr)

6.41%

TGTX Earnings

Earnings (TTM)

461.9M

Earnings Growth (Yr)

290.85%

Earnings Growth (Qtr)

-14.15%

TGTX Profitability

EBT Margin

17.46%

Return on Equity

79.21%

Return on Assets

30.21%

Free Cashflow Yield

-0.19%

TGTX Investor Care

Buy Backs (1Y)

3.21%

Diluted EPS (TTM)

2.87

TGTX Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026700.3M000
2025386.4M454.1M531.9M616.3M
2024289.3M346.7M264.8M329.0M
20238.6M24.1M189.8M233.7M
20227.9M7.0M5.0M2.8M
2021907.0K2.4M4.4M6.7M
2020152.0K152.0K152.0K152.0K
2019152.0K152.0K152.0K152.0K
2018148.5K148.5K148.5K152.0K
2017152.9K153.8K154.6K155.5K
2016229.4K290.5K322.5K152.0K
201586.9K118.8K150.7K182.6K
201436.9K42.9K49.0K55.0K
201350.2K84.2K117.4K30.8K
201200015.8K
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About TG Therapeutics Inc

TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
 CEO
 WEBSITEtgtherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES244

TG Therapeutics Inc Frequently Asked Questions

TGTX is the stock ticker symbol of TG Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of TG Therapeutics Inc is 7.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, TGTX's PE ratio (Price to Earnings) is 16.42 and Price to Sales (PS) ratio is 10.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TGTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, TG Therapeutics Inc has provided 0.216 (multiply by 100 for percentage) rate of return.